ARTICLE | Clinical News
Sanofi's semuloparin meets VTE endpoint
June 7, 2011 12:20 AM UTC
Sanofi (Euronext:SAN; NYSE:SNY) said semuloparin met the primary endpoint vs. placebo in the Phase III SAVE-ONCO trial to prevent venous thromboembolism (VTE) in cancer patients undergoing chemotherap...